Johnson & Johnson Earnings Beat Estimates, J&J Raises 2026 Outlook Despite Stelara Slump
Johnson & Johnson reported first-quarter revenue of $24.1 billion, up 9.9%, and adjusted earnings of $2.70 per share, both above analyst estimates. Sales of cancer drug Darzalex hit $4 billion, while Stelara fell 60% to $656 million. The company raised its 2026 outlook, nudging full-year sales guidance to $100.8 billion. J&J shares slipped 0.27% to $237.96 in early trading.